Skip to content

Colonic Propionate, Appetite, and Weight Loss

Effect of Increased Colonic Propionate on Weight Loss During a Hypo-caloric Diet.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03322514
Acronym
ProAp
Enrollment
12
Registered
2017-10-26
Start date
2017-03-29
Completion date
2017-11-11
Last updated
2019-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appetite Regulation, Healthy Obesity, Metabolically

Keywords

gut hormones, obesity, appetite, propionate, fermentation

Brief summary

The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

Detailed description

DIET AND OBESITY: Obesity has reached epidemic proportions worldwide. In the United Kingdom, 58% of adult women and 65% of adult men are either overweight or obese (Health and Social Care Information Centre 2014), with the expectation that rates will increase (Ng et al. 2014). Obesity, mainly caused by a chronic positive energy balance, is a known risk factor that contributes to the development of type 2 diabetes and cardiovascular diseases, and the subsequent morbidities and mortalities (Kopelman 2007). A positive energy balance is inevitable with the composition of current western diet that contain refined (fibre-depleted) carbohydrates that are consumed quickly, and have minimal effects on long-term satiety (Cleave 1974; Heaton 1973). NONDIGESTIBLE CARBOHYDRATES: The quality and quantity of diet has changed dramatically over the last fifty years. Of which, carbohydrates have the most significant changes; from unprocessed fruits and vegetables based carbohydrates to more processed cereal based ones (Cordain et al. 2005). Epidemiological studies have shown that, as a result, ancestral diets had greater amounts of Non-Digestible Carbohydrates (NDC) than modern diets (\>100g/day compared to \<15g/day) with the inclusion of more indigestible intact cell wall plant material, such as tubers, grasses and sedges (Eaton 2006). A strong association has been established between increased weight gain with decreased NDC intake (Liu et al. 2003). Furthermore, increasing intake of NDC have shown to induce satiety and improve body composition in animals (So et al. 2007) and humans (Bouché et al. 2002). LOW CALORIC HIGH NDC DIET IN LOSING WEIGHT Applying energy-restricted diets is one of the first steps to treat obesity. However, weight regain in weight maintenance period could happen due to resting energy expenditure reduction and lean mass loss. The inclusion of specific foods to the nutritional intervention is being investigated in order to produce persistent weight losses (Abete et al. 2008). It was suggested earlier that the addition of high fibre NDC foods to a hypocaloric diet would help reducing the incidence of metabolic syndrome and increasing the dietary compliance (Hermana et al, 2011). The high fibre content in combination with a low glycemic index diet, can both result in higher satiety effects with an increased mitochondrial oxidation, all favour weight loss. PROPIONATE AND THE FFAR2 RECEPTOR: Production of short chain fatty acids (SCFA) is the main by-product of NDC colonic fermentation (Pawlak et al. 2004). Of them, colonic propionate was found to play a critical role directly in the colon and systematically after its absorption into the circulation (Wong et al. 2006). Free Fatty Acid Receptor 2 (previously known as orphan G-coupled Protein Receptor 43) has been discovered to has high affinity to propionate (Brown et al. 2003). It is expressed on the distal ileum and colon L-enteroendocrine cells (Karaki et al. 2008), adipocytes and certain monocytes lineage (Hong et al. 2005). THE ROLE OF PROPIONATE IN GUT HORMONE RELEASE AND APPETITE REGULATION: The L-enteroendocrine colonic cells are responsible of secreting anorexic gut hormones (PYY and GLP-1) physiologically in response to food. These hormones are capable of inducing satiety through signalling the brain appetite centre (Murphy & Bloom 2006). Propionate-induced FFAR2 activation have found to cause the release of these hormones in vitro. Moreover, NDC ingestion was found to stimulate the release of these hormones in animals, resulting in decreasing food ingestion (Delzenne et al. 2005). Propionate was shown to replicate the same effects in further studies, suggesting the owning of the beneficial effects of NDC on appetite and gut hormones to propionate production. SHORT CHAIN FATTY ACID ESTER: Administering NDCs that promote the production of propionate is an attractive way to increase the level of propionate over an extended period of time. However, due to variability of the gut microbita activity, administering high proportions (≥ 35g/d) of dietary fibres in human diets to increase colonic propionate does not reliably or predictably provide the same SCFA levels in colon or systemically (Cummings 1981). Oral propionate supplementation is another method, but unfortunately its short plasma half-life, poor palatability, and the fact that its main absorption happens in the small intestine limit its use as a food supplement (Frost et al. 2003). A novel system has been developed by Dr Douglas Morrison, (Scottish Universities Environmental Research Centre (SUERC)). This molecule of inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester) was demonstrated to reliably and reproducibly increase colonic propionate while prevent the side effects of NDC (Chambers et al. 2015). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora, which was estimated to be 180 minutes post-ingestion. (Chambers et al. 2014). Chambers et al. (2015) were able to show that 10g of Inulin-Propionate Esters (IPE) has the ability to deliver 2.4g of propionate to the colon, that is an increment of 2.5-fold of propionate production in the colon, a level that is achieved only with 60g/d via traditional dietary fibre supplementation. The same group has also demonstrated that while the acute administration of this supplement caused increments in Plasma GLP-1 and PYY and reduced food ingestion, the long term (24 weeks) supplementation of propionate ester significantly reduced body weight gain and the development of abdominal adipose tissue (Chambers et al. 2014). Interestingly, none of the long term participants reported any side effects from the intake of propionate esters. Increasing colonic propionate is, therefore, one of the attractive strategies to manage weight and diabetes risk factors. The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

Interventions

DIETARY_SUPPLEMENTInulin-Propionate Esters

Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.

DIETARY_SUPPLEMENTInulin

Inulin

Sponsors

University of Glasgow
CollaboratorOTHER
Imperial College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

double blind, randomised, controlled, paralleled study

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* overweight or obese ((BMI) of 25-35 kg/m2) * healthy * aged between 18 and 65 years

Exclusion criteria

* Weight change of ≥ 3kg in the preceding 2 months * Undergone any weight loss surgery or gastric procedures to promote weight loss * Current smokers * Substance abuse * Excess alcohol intake * Pregnancy * Diabetes * Cardiovascular disease * Cancer * Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome * Kidney disease * Liver disease * Pancreatitis * Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones. Any participants with the above conditions would already have an altered pattern of hormones and inflammatory molecules because of their disease process and would therefore give us confounding or misleading results.

Design outcomes

Primary

MeasureTime frameDescription
Change in Weight Loss Compared to BaselineBaseline and 12 weeksThe weight assessed by a body scale

Secondary

MeasureTime frame
Glucose Blood Level Baseline to 12 WeeksBaseline, 12 weeks
Insulin Level in SerumBaseline, 12 weeks

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
Experimental Group
10 g of Inulin-Propionate Esters will be administered per day Inulin-Propionate Esters: Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
6
Inulin
10 g of Inulin will be administered per day Inulin: Inulin
6
Total12

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject11

Baseline characteristics

CharacteristicInulinTotalExperimental Group
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
6 Participants12 Participants6 Participants
Age, Continuous35.2 years
STANDARD_DEVIATION 12.1
33.4 years
STANDARD_DEVIATION 8.9
30.6 years
STANDARD_DEVIATION 5.9
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United Kingdom
6 participants12 participants6 participants
Sex: Female, Male
Female
5 Participants9 Participants4 Participants
Sex: Female, Male
Male
1 Participants3 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 60 / 6
other
Total, other adverse events
0 / 60 / 6
serious
Total, serious adverse events
0 / 60 / 6

Outcome results

Primary

Change in Weight Loss Compared to Baseline

The weight assessed by a body scale

Time frame: Baseline and 12 weeks

ArmMeasureValue (MEAN)Dispersion
Experimental GroupChange in Weight Loss Compared to Baseline-2.6 kgStandard Error 0.9
InulinChange in Weight Loss Compared to Baseline-3 kgStandard Error 1.04
p-value: 0.8t-test, 2 sided
Comparison: Baseline to 12 weeksp-value: 0.04t-test, 2 sided
Comparison: Baseline to 12 weeksp-value: 0.1t-test, 2 sided
Secondary

Glucose Blood Level Baseline to 12 Weeks

Time frame: Baseline, 12 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Experimental GroupGlucose Blood Level Baseline to 12 WeeksBaseline4.9 mmol/LStandard Error 0.1
Experimental GroupGlucose Blood Level Baseline to 12 Weeks12 weeks5.1 mmol/LStandard Error 0.1
InulinGlucose Blood Level Baseline to 12 WeeksBaseline4.4 mmol/LStandard Error 0.1
InulinGlucose Blood Level Baseline to 12 Weeks12 weeks4.8 mmol/LStandard Error 0.1
p-value: 0.8ANOVA
Comparison: Baseline to 12 weeksp-value: 0.3t-test, 2 sided
Comparison: Baseline to 12 weeksp-value: 0.3t-test, 2 sided
Secondary

Insulin Level in Serum

Time frame: Baseline, 12 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Experimental GroupInsulin Level in SerumBaseline50.4 mU/mLStandard Error 10.8
Experimental GroupInsulin Level in Serum12 weeks41.0 mU/mLStandard Error 6.7
InulinInsulin Level in SerumBaseline48.9 mU/mLStandard Error 18.3
InulinInsulin Level in Serum12 weeks46.0 mU/mLStandard Error 21.1
p-value: 0.9ANOVA
Comparison: Baseline to 12 weeksp-value: 0.4t-test, 2 sided
Comparison: baseline to 12 weeksp-value: 0.7t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026